{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T11:22:46Z","timestamp":1777116166842,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100008257","name":"Tarbiat Modares University","doi-asserted-by":"publisher","award":["Med79865, and IG-39803"],"award-info":[{"award-number":["Med79865, and IG-39803"]}],"id":[{"id":"10.13039\/501100008257","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008257","name":"Tarbiat Modares University","doi-asserted-by":"publisher","award":["Med79865, and IG-39803"],"award-info":[{"award-number":["Med79865, and IG-39803"]}],"id":[{"id":"10.13039\/501100008257","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003968","name":"Iran National Science Foundation","doi-asserted-by":"publisher","award":["INSF4004518"],"award-info":[{"award-number":["INSF4004518"]}],"id":[{"id":"10.13039\/501100003968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s00210-024-03314-1","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T10:02:41Z","timestamp":1721815361000},"page":"715-727","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Deferiprone promoted remyelination and functional recovery through enhancement of oligodendrogenesis in experimental demyelination animal model"],"prefix":"10.1007","volume":"398","author":[{"given":"Atefeh","family":"Rayatpour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Forough","family":"Foolad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2045-6171","authenticated-orcid":false,"given":"Mohammad","family":"Javan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"key":"3314_CR1","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.freeradbiomed.2018.04.002","volume":"120","author":"S Agrawal","year":"2018","unstructured":"Agrawal S et al (2018) Brain mitochondrial iron accumulates in Huntington\u2019s disease, mediates mitochondrial dysfunction, and can be removed pharmacologically. Free Radical Biol Med 120:317\u2013329","journal-title":"Free Radical Biol Med"},{"issue":"6","key":"3314_CR2","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s10534-018-0135-1","volume":"31","author":"LA Alcalde","year":"2018","unstructured":"Alcalde LA et al (2018) Iron chelator deferiprone rescues memory deficits, hippocampal BDNF levels and antioxidant defenses in an experimental model of memory impairment. Biometals 31(6):927\u2013940","journal-title":"Biometals"},{"issue":"5457","key":"3314_CR3","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/249577a0","volume":"249","author":"W Blakemore","year":"1974","unstructured":"Blakemore W (1974) Pattern of remyelination in the CNS. Nature 249(5457):577\u2013578","journal-title":"Nature"},{"key":"3314_CR4","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S0074-7742(07)79026-8","volume":"79","author":"DM Chari","year":"2007","unstructured":"Chari DM (2007) Remyelination in multiple sclerosis. Int Rev Neurobiol 79:589\u2013620","journal-title":"Int Rev Neurobiol"},{"issue":"3","key":"3314_CR5","first-page":"527","volume":"140","author":"J Correale","year":"2017","unstructured":"Correale J et al (2017) Progressive multiple sclerosis: from pathogenic mechanisms to treatment. Brain 140(3):527\u2013546","journal-title":"Brain"},{"key":"3314_CR6","doi-asserted-by":"publisher","unstructured":"Daglas M et al (2022) Deferiprone attenuates neuropathology and improves outcome following traumatic brain injury. Br J Pharmacol. https:\/\/doi.org\/10.1111\/bph.15950","DOI":"10.1111\/bph.15950"},{"issue":"1","key":"3314_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s12031-012-9777-6","volume":"48","author":"S Dehghan","year":"2012","unstructured":"Dehghan S et al (2012) Basic fibroblast growth factor potentiates myelin repair following induction of experimental demyelination in adult mouse optic chiasm and nerves. J Mol Neurosci 48(1):77\u201385","journal-title":"J Mol Neurosci"},{"key":"3314_CR8","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.neuroscience.2016.01.028","volume":"318","author":"S Dehghan","year":"2016","unstructured":"Dehghan S et al (2016) Oct4 transcription factor in conjunction with valproic acid accelerates myelin repair in demyelinated optic chiasm in mice. Neuroscience 318:178\u2013189","journal-title":"Neuroscience"},{"key":"3314_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneumeth.2021.109088","volume":"352","author":"S Dehghan","year":"2021","unstructured":"Dehghan S et al (2021) An optimized animal model of lysolecithin induced demyelination in optic nerve; more feasible, more reproducible, promising for studying the progressive forms of multiple sclerosis. J Neurosci Methods 352:109088","journal-title":"J Neurosci Methods"},{"issue":"2","key":"3314_CR10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1089\/ars.2013.5593","volume":"21","author":"D Devos","year":"2014","unstructured":"Devos D et al (2014) Targeting chelatable iron as a therapeutic modality in Parkinson\u2019s disease. Antioxid Redox Signal 21(2):195\u2013210","journal-title":"Antioxid Redox Signal"},{"issue":"2","key":"3314_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00702-010-0531-3","volume":"118","author":"DT Dexter","year":"2011","unstructured":"Dexter DT et al (2011) Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson\u2019s disease after peripheral administration. J Neural Transm 118(2):223\u2013231","journal-title":"J Neural Transm"},{"key":"3314_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2019.112314","volume":"378","author":"SF Fawzi","year":"2020","unstructured":"Fawzi SF, Menze ET, Tadros MG (2020) Deferiprone ameliorates memory impairment in scopolamine-treated rats: the impact of its iron-chelating effect on \u03b2-amyloid disposition. Behav Brain Res 378:112314","journal-title":"Behav Brain Res"},{"issue":"11","key":"3314_CR13","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nrn2480","volume":"9","author":"RJ Franklin","year":"2008","unstructured":"Franklin RJ (2008) Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci 9(11):839\u2013855","journal-title":"Nat Rev Neurosci"},{"issue":"12","key":"3314_CR14","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/nrn.2017.136","volume":"18","author":"RJ Franklin","year":"2017","unstructured":"Franklin RJ (2017) Regenerating CNS myelin\u2014from mechanisms to experimental medicines. Nat Rev Neurosci 18(12):753\u2013769","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"3314_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12883-015-0331-3","volume":"15","author":"G Grolez","year":"2015","unstructured":"Grolez G et al (2015) Ceruloplasmin activity and iron chelation treatment of patients with Parkinson\u2019s disease. BMC Neurol 15(1):1\u20136","journal-title":"BMC Neurol"},{"issue":"8","key":"3314_CR16","doi-asserted-by":"publisher","first-page":"825","DOI":"10.3390\/cells8080825","volume":"8","author":"J Gruchot","year":"2019","unstructured":"Gruchot J et al (2019) The molecular basis for remyelination failure in multiple sclerosis. Cells 8(8):825","journal-title":"Cells"},{"issue":"2","key":"3314_CR17","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1167\/iovs.10-6207","volume":"52","author":"M Hadziahmetovic","year":"2011","unstructured":"Hadziahmetovic M et al (2011) The oral iron chelator deferiprone protects against iron overload\u2013induced retinal degeneration. Invest Ophthalmol vis Sci 52(2):959\u2013968","journal-title":"Invest Ophthalmol vis Sci"},{"issue":"3","key":"3314_CR18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1167\/tvst.1.3.2","volume":"1","author":"M Hadziahmetovic","year":"2012","unstructured":"Hadziahmetovic M et al (2012) The oral iron chelator deferiprone protects against retinal degeneration induced through diverse mechanisms. Transl Vis Sci Technol 1(3):2\u20132","journal-title":"Transl Vis Sci Technol"},{"issue":"5","key":"3314_CR19","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1046\/j.1365-2990.2003.00491.x","volume":"29","author":"J Holley","year":"2003","unstructured":"Holley J et al (2003) Astrocyte characterization in the multiple sclerosis glial scar. Neuropathol Appl Neurobiol 29(5):434\u2013444","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"6","key":"3314_CR20","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1093\/brain\/awn080","volume":"131","author":"K Irvine","year":"2008","unstructured":"Irvine K, Blakemore W (2008) Remyelination protects axons from demyelination-associated axon degeneration. Brain 131(6):1464\u20131477","journal-title":"Brain"},{"issue":"7","key":"3314_CR21","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S1474-4422(19)30142-5","volume":"18","author":"T Klopstock","year":"2019","unstructured":"Klopstock T et al (2019) Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study. The Lancet Neurology 18(7):631\u2013642","journal-title":"The Lancet Neurology"},{"issue":"2","key":"3314_CR22","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S1474-4422(14)70256-X","volume":"14","author":"DH Mahad","year":"2015","unstructured":"Mahad DH, Trapp BD, Lassmann H (2015) Pathological mechanisms in progressive multiple sclerosis. The Lancet Neurology 14(2):183\u2013193","journal-title":"The Lancet Neurology"},{"issue":"1","key":"3314_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-01402-2","volume":"7","author":"A Martin-Bastida","year":"2017","unstructured":"Martin-Bastida A et al (2017) Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson\u2019s disease. Sci Rep 7(1):1\u20139","journal-title":"Sci Rep"},{"key":"3314_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jneumeth.2018.10.038","volume":"313","author":"LA Mesentier-Louro","year":"2019","unstructured":"Mesentier-Louro LA et al (2019) Direct targeting of the mouse optic nerve for therapeutic delivery. J Neurosci Methods 313:1\u20135","journal-title":"J Neurosci Methods"},{"issue":"3","key":"3314_CR25","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.neuroscience.2004.07.053","volume":"129","author":"G Metz","year":"2004","unstructured":"Metz G, Schwab M (2004) Behavioral characterization in a comprehensive mouse test battery reveals motor and sensory impairments in growth-associated protein-43 null mutant mice. Neuroscience 129(3):563\u2013574","journal-title":"Neuroscience"},{"issue":"9","key":"3314_CR26","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1177\/1352458507078916","volume":"13","author":"K Mitchell","year":"2007","unstructured":"Mitchell K et al (2007) Deferiprone, an orally deliverable iron chelator, ameliorates experimental autoimmune encephalomyelitis. Mult Scler J 13(9):1118\u20131126","journal-title":"Mult Scler J"},{"key":"3314_CR27","unstructured":"Moreau C et al (2018) Could conservative iron chelation lead to neuroprotection in amyotrophic lateral sclerosis? Mary Ann Liebert, Inc., New Rochelle"},{"key":"3314_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcn.2019.103391","volume":"99","author":"P Niknam","year":"2019","unstructured":"Niknam P et al (2019) Modulating proteoglycan receptor PTP\u03c3 using intracellular sigma peptide improves remyelination and functional recovery in mice with demyelinated optic chiasm. Mol Cell Neurosci 99:103391","journal-title":"Mol Cell Neurosci"},{"issue":"4","key":"3314_CR29","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.stem.2019.09.003","volume":"25","author":"H Nobuta","year":"2019","unstructured":"Nobuta H et al (2019) Oligodendrocyte death in Pelizaeus-Merzbacher disease is rescued by iron chelation. Cell Stem Cell. 25(4):531\u2013541. https:\/\/doi.org\/10.1016\/j.stem.2019.09.003","journal-title":"Cell Stem Cell."},{"key":"3314_CR30","unstructured":"Paxinos G, Franklin KBJ (2019) Paxinos and Franklin\u2019s the mouse brain in stereotaxic coordinates, 5th edn. Academic press"},{"issue":"1","key":"3314_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1523\/JNEUROSCI.2844-17.2017","volume":"38","author":"C Pearson","year":"2018","unstructured":"Pearson C (2018) A therapeutic link between astrogliosis and remyelination in a mouse model of multiple sclerosis. J Neurosci 38(1):29\u201331","journal-title":"J Neurosci"},{"issue":"9","key":"3314_CR32","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1172\/JCI90610","volume":"127","author":"T Philips","year":"2017","unstructured":"Philips T, Rothstein JD (2017) Oligodendroglia: metabolic supporters of neurons. J Clin Investig 127(9):3271\u20133280","journal-title":"J Clin Investig"},{"issue":"9","key":"3314_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106378","volume":"9","author":"F Pourabdolhossein","year":"2014","unstructured":"Pourabdolhossein F et al (2014) Nogo receptor inhibition enhances functional recovery following lysolecithin-induced demyelination in mouse optic chiasm. PLoS ONE 9(9):e106378","journal-title":"PLoS ONE"},{"issue":"1","key":"3314_CR34","doi-asserted-by":"publisher","first-page":"19630","DOI":"10.1038\/s41598-022-24152-2","volume":"12","author":"A Rayatpour","year":"2022","unstructured":"Rayatpour A et al (2022) Ferroptosis inhibition by deferiprone, attenuates myelin damage and promotes neuroprotection in demyelinated optic nerve. Sci Rep 12(1):19630","journal-title":"Sci Rep"},{"key":"3314_CR35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.nbd.2018.11.018","volume":"124","author":"MS Seyedsadr","year":"2019","unstructured":"Seyedsadr MS et al (2019) Inactivation of sphingosine-1-phosphate receptor 2 (S1PR2) decreases demyelination and enhances remyelination in animal models of multiple sclerosis. Neurobiol Dis 124:189\u2013201","journal-title":"Neurobiol Dis"},{"issue":"7","key":"3314_CR36","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1248\/bpb.b15-00185","volume":"38","author":"Y Shirai","year":"2015","unstructured":"Shirai Y et al (2015) Deferiprone protects against photoreceptor degeneration induced by tunicamycin in the rat retina. Biol Pharm Bull 38(7):1076\u20131080","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"3314_CR37","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.freeradbiomed.2012.04.020","volume":"53","author":"D Song","year":"2012","unstructured":"Song D et al (2012) Systemic administration of the iron chelator deferiprone protects against light-induced photoreceptor degeneration in the mouse retina. Free Radical Biol Med 53(1):64\u201371","journal-title":"Free Radical Biol Med"},{"issue":"7","key":"3314_CR38","doi-asserted-by":"publisher","first-page":"4525","DOI":"10.1167\/iovs.14-14568","volume":"55","author":"D Song","year":"2014","unstructured":"Song D et al (2014) The oral iron chelator deferiprone protects against systemic iron overload\u2013induced retinal degeneration in hepcidin knockout mice. Invest Ophthalmol vis Sci 55(7):4525\u20134532","journal-title":"Invest Ophthalmol vis Sci"},{"issue":"13","key":"3314_CR39","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1002\/glia.20546","volume":"55","author":"A Williams","year":"2007","unstructured":"Williams A, Piaton G, Lubetzki C (2007) Astrocytes\u2014friends or foes in multiple sclerosis? Glia 55(13):1300\u20131312","journal-title":"Glia"},{"key":"3314_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41418-022-01046-4","volume":"30","author":"F Yao","year":"2022","unstructured":"Yao F et al (2022) Pathologically high intraocular pressure disturbs normal iron homeostasis and leads to retinal ganglion cell ferroptosis in glaucoma. Cell Death Differ 30:1\u201313. https:\/\/doi.org\/10.1038\/s41418-022-01046-4","journal-title":"Cell Death Differ"},{"key":"3314_CR41","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.neuroscience.2015.10.013","volume":"311","author":"A Yazdi","year":"2015","unstructured":"Yazdi A, Baharvand H, Javan M (2015) Enhanced remyelination following lysolecithin-induced demyelination in mice under treatment with fingolimod (FTY720). Neuroscience 311:34\u201344","journal-title":"Neuroscience"},{"issue":"3","key":"3314_CR42","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s10534-018-0111-9","volume":"31","author":"E Zakharova","year":"2018","unstructured":"Zakharova E et al (2018) Erythropoietin and Nrf2: key factors in the neuroprotection provided by apo-lactoferrin. Biometals 31(3):425\u2013443","journal-title":"Biometals"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03314-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-024-03314-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03314-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T08:59:38Z","timestamp":1738400378000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-024-03314-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["3314"],"URL":"https:\/\/doi.org\/10.1007\/s00210-024-03314-1","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,24]]},"assertion":[{"value":"6 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed on animal were approved by the Ethics Committee for Biomedical Research at Tarbiat Modares University (Ethical approved ID: IR.MODARES.REC.1398.005).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}